E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Myelodysplastic Syndromes
Acute Myeloid Leukaemia
Chronic Myelomonocytic Leukaemia |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054350 |
E.1.2 | Term | Chronic myelomonocytic leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000886 |
E.1.2 | Term | Acute myeloid leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10000880 |
E.1.2 | Term | Acute myeloid leukaemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028533 |
E.1.2 | Term | Myelodysplastic syndrome |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10009018 |
E.1.2 | Term | Chronic myelomonocytic leukaemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the overall response rate (CR+PR as per IWG 2006) at 6 months in MDS patients, CMML-2 patients, and AML patients with up to 30% bone marrow blasts (previously classified as RAEB-t by the FAB MDS classification), treated with low-dose decitabine who have previously failed therapy with 5-azacitidine. |
|
E.2.2 | Secondary objectives of the trial |
To assess overall survival.
To assess time to AML progression or death.
To assess haematological improvement.
To assess transfusion requirements.
To assess cytogenetics response.
To assess grade 3 and 4 treatment related toxicity
To assess additional cytogenic markers: DNA methylation status, markers of apoptosis, change in gene expression and Single Nucleotide Polymorphism Profiles. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Written signed informed consent.
2. 18 years of age or older
3. At study entry, diagnosed MDS with 5% or more marrow blasts and IPSS risk intermediate 2 or high risk; or chronic myelomonocytic leukemia (CMML-2); or AML with 20-30% bone marrow blasts (previously defined as RAEB-t by the FAB MDS classification).
4. Patients who have failed therapy with azacitidine* see definition below.
5. Performance status 0-2 (ECOG scale).
6. Adequate hepatic (bilirubin < 1.5 X ULN or AST< 2.5 X ULN) and renal functions (creatinine <1.5 X ULN).
*Failure of treatment with 5-azacitidine is defined as:
1. Refractory
Progression, immediately and without reaching prior response (CR, PR, mCR, HI), under therapy with 5-azacitidine given for at least 6 cycles
2. Relapsed on therapy
Progression, after prior response (CR, PR, mCR, HI, SD), under therapy with 5-azacitidine
3. Relapsed off therapy
Patients who had previously attained a response (CR, PR, mCR, HI, SD) while on 5-azacitidine, but have subsequently relapsed within 3 months from last 5-azacitidine course
4. Toxicity failure
5-azacitidine-related non-haematological toxicity precluding its further administration
|
|
E.4 | Principal exclusion criteria |
1. Patients with >30% bone marrow blasts at study entry.
2. Nursing and pregnant females.
3. Women of childbearing potential (WCBP) † and males not willing to practice an effective method of contraception whilst receiving decitibine and for 2 months after the last infusion.
† A woman of child-bearing potential is a sexually mature woman who has not undergone a hysterectomy or bilateral oopherectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses at any time in the preceding 24 consecutive months).
4. Patients with concurrent malignancy.
5. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure and unstable angina pectoris.
6. Ongoing oral corticosteroids are not permitted. However, use of corticosteroids (topical and inhaled) is permitted and prophylactic steroids are allowed for transfusion reactions.
7. Patients who have received any investigational agent within the 30 days preceding the first dose of study drug.
8. Patients who have received prior intensive combination chemotherapy or high-dose cytarabine (>/= 1g/m*2 per dose) for the treatment of MDS or AML. (Prior biologic therapies, targeted therapies and single agent chemotherapy are allowed).
9. Patients who have an active viral or bacterial infection. Note: No patient is allowed to enter the study unless infections have been fully treated and the patient has remained afebrile for 7 days without antibiotics.
10. Patients who have concurrent autoimmune hemolytic anemia or immune thrombocytopenia.
11. Patients who have previously been treated with decitabine.
12. Patients who have known positive serology for HIV.
13. Patients with a condition that may be unable to comply with the treatment and monitoring requirements of the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Duration of response is defined as the interval from date complete or partial remission is documented to date of recurrence/progression, death due to any cause, or lost to follow-up. |
|
E.5.2 | Secondary end point(s) |
1) Overall survival
2) Time to AML
3) Hematologic Improvement
Hematologic improvements (HI) must last at least 2 months in the absence of ongoing cytotoxic therapy). Hematologic improvement should be described by the number of individual, positively affected cell lines (e.g., HI-E; HI-E + HI-N; HI-E + HI-P + HI-N).
4) Erythroid response (HI-E) Hgb increase by 1.5 g/dL.
5) Platelet response (HI-P)
Absolute increase of 30 x 109/L for patients starting with > 20 x 109/L platelets. Increase from < 20 x 109/L to > 20 x 109/L and by at least 100%.
6) Neutrophil response (HI-N)
At least 100% increase and an absolute increase > 0.5 x 109/L.
7) Transfusion requirements
Transfusion requirements will be recorded for each patient for the 8-week period before first dose of study drug and during the trial. To be considered transfusion independent, patients must not have received transfusions or medications to stimulate production ofred or white blood cells or platelets for a period of 8 weeks.
8) Cytogenetic Response Rate
Cytogenetic response requires 20 analyzable metaphases using conventional cytogenetic techniques.
9) Treatment Related Toxicity
Toxicity will be scored using CTC Version 3.0 for toxicity and adverse event reporting. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) Overall survival is defined as the date of first dose of study drug to the date of death from any cause.
2) Time to AML is defined as the date of the first dose of study drug to the first date that the patient is confirmed to have AML (≥20% blasts in bone marrow)
3) 30 days post last dose
4) 30 days post last dose
5) 30 days post last dose
6) 30 days post last dose
7) 30 days post last dose
8) 30 days post last dose
9) 30 days post last dose
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
last visit of the last subject undergoing the trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |